98%
921
2 minutes
20
Objective: Our study was a prospective in vivo study performed on an animal model to evaluate the safety and performance of a novel venous stent designed specifically for venous applications.
Methods: The novel stents were implanted in the inferior vena cava of nine sheep. The stents were deployed with different distances between the closed cell rings to test for if the segments might migrate after being deployed at maximal distance. Three different total lengths were 9, 11, and 13 cm. After 1, 3, and 6 months, vascular injury, thrombus, neointima coverage, and stent migration were evaluated through computed tomography venography and histopathology. Imaging, histology, and integration data were analyzed for each group.
Results: All stents were deployed successfully, and all sheep survived until the time of harvesting. In all cases, the native blood vessel sections were intact. The segmented stent parts showed a differently pronounced tissue coverage, depending on the duration of the implantation.
Conclusions: The new nitinol stent is safe and feasible to implant in the venous system with a rapid surface coverage. Alteration of stent length did not affect the development of neointimal formation and did not cause migration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318499 | PMC |
http://dx.doi.org/10.1016/j.jvssci.2023.100113 | DOI Listing |
Anal Methods
September 2025
Key Laboratory of Biorheological Science and Technology of Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400044, P. R. China.
Aflatoxin B1 (AFB1) is one of the most toxic mycotoxins that pose great health threats to humans. Herein, an aptasensor-based fluorescent signal amplification strategy is developed for the detection of AFB1. Initially, the AFB1 aptamers labelled with carboxyfluorescein (FAM) are adsorbed onto graphene oxide (GO), triggering energy transfer.
View Article and Find Full Text PDFNanotoxicology
September 2025
Department of Biophysics of Environmental Pollution, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
The effect of non-functionalized polystyrene nanoparticles (PS-NPs) with diameters of 29, 44, and 72 nm on plasmid DNA integrity and the expression of genes involved in the architecture of chromatin was investigated in human peripheral blood mononuclear cells (PBMCs). The cells were incubated with PS-NPs at concentrations ranging from 0.001 to 100 µg/mL for 24 hours.
View Article and Find Full Text PDFRetin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
Mol Ther Methods Clin Dev
June 2025
Precision Safety, Pharma Product Development, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
Adeno-associated virus (AAV) vectors are widely used in gene therapy, particularly for liver-targeted treatments. However, predicting human-specific outcomes, such as transduction efficiency and hepatotoxicity, remains challenging. Reliable models are urgently needed to bridge the gap between preclinical studies and clinical applications.
View Article and Find Full Text PDFMed Acupunct
August 2025
The Japan Society of Acupuncture and Moxibustion, Tokyo, Japan.
Introduction: The Japan Society of Acupuncture and Moxibustion (JSAM) and experts on the safety of acupuncture and moxibustion (AM) in Japan have focused on safety improvement among acupuncturists, moxibustionists (AMists), and AM-practicing physicians. This article provides an overview of the activities conducted by academic experts in AM safety, primarily from the JSAM, to improve AM safety.
Discussion: The JSAM formed the Safety Committee in 1998 to collect data regarding AM-related adverse events, provide relevant information to members, and conduct educational activities to prevent malpractice.